Streetwise Expert Interviews

John Hester

Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester of Bell Potter Securities

Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.

(7/22/15) More >
Read More Streetwise Interviews

Four Small-Cap Medtechs Primed for Outsize Returns: Zacks' Brian Marckx

Brian Marckx of Zacks Investment Research describes changes in regulations affecting the medical device and diagnostics industries, and identifies innovative companies poised to make the most of the situation. (7/15/15) More >

Newsletter Briefs

"Development of AEMD's Hemopurifier continues to ramp up, and results to date look very encouraging." (7/15/15) Aethlon Medical Inc. - The Life Sciences Report Interview with Brian Marckx More >

"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." (7/8/15) Resverlogix Corp. - The Life Sciences Report Interview with Jason Napodano More >

"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >

"I think a large pharma company would be very interested in CTRV's FV-100." (7/8/15) ContraVir Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Napodano More >

"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS." (7/8/15) BrainStorm Cell Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >

"We believe RGS has the potential to become Australia's next success story in regenerative medicine." (7/1/15) Regeneus Ltd. - The Life Sciences Report Interview with Marcel Wijma More >

"RVX may have the answer to developing a new generation of cardio drugs." (7/1/15) Resverlogix Corp. - The Life Sciences Report Interview with Marcel Wijma More >

"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

Expert Analysis

"2015 is a year of inflection for STEM." (7/20/15) StemCells Inc. - Jason Kolbert, Maxim Group More >

"KOLs have enthusiasm and belief in CPXX's Vyxeos following the response rates observed in the Phase 2." (7/17/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"MSB's current program has been both positive and robust." (7/15/15) Mesoblast Ltd. - Jason Kolbert, Maxim Group More >

"We continue to be impressed by the physician commentary surrounding CPXX's CPX-351 data." (7/14/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CBMG represents an opportunity for savvy investors." (7/13/15) Cellular Biomedicine Group Inc. - Stephen Dunn, LifeTech Capital More >

"NHC's new CFO, Kenny Klein, adds post-transaction integration experience." (7/9/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >

"RESX has a well-experienced management team." (7/8/15) RestorGenex Corp. - Ajay Tandon, SeeThruEquity More >

"We expect NHC's positive sales and margin momentum to continue in 2015." (7/6/15) Nobilis Health Corp. - Sheila Broughton, PI Financial More >